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COST-EFFECTIVENESS OF RABEPRAZOLE 
VERSUS RANITIDINE IN REFLUX ESOPHAGITIS
Ofman JJ1, Yamashita BD2, Siddique RS3, Larson LR2, Willian 
MK3
1Cedars Sinai/Zynx Health Inc., Los Angeles, CA, USA; 
2Ovation Research Group, Highland Park, IL, USA; 3Janssen 
Pharmaceutica, Titusville, NJ, USA
OBJECTIVE: Compare cost-effectiveness of rabeprazole
(RAB) versus ranitidine (RAN) in acute and maintenance
therapy of erosive esophagitis using symptom response,
rather than endoscopic healing, as the outcome.
METHODS: Cost-effectiveness was assessed in a decision
analysis model based on clinical-trial and published data.
Costs reflected 1998 Medicare reimbursement, generic
RAN, and estimated AWP for RAB. Cost per symptom-
atic recurrence prevented over 1 year of maintenance ther-
apy is reported as average and incremental cost-effective-
ness ratios (ACER, ICER). Patients were initially treated
with RAB 20 mg QD or RAN 150 mg QID for 8 weeks.
Asymptomatic RAB patients received RAB 20 mg QD
maintenance, while asymptomatic RAN patients received
RAN 150 mg BID. Symptomatic RAB patients received
dose escalation, and symptomatic RAN patients were
switched to RAB therapy. Non-responders were evaluated
for surgery. Recurrences were treated with RAB 40 mg or
RAN 300 mg BID. If RAN patients required RAB for
acute therapy, they received RAN 300 BID maintenance.
Symptomatic recurrences on RAN 300mg BID mainte-
nance were treated with RAB, followed with RAB mainte-
nance. Up to two symptomatic recurrences were allowed.
RESULTS: Average per-patient costs were higher with
RAB (RAB $2020 versus RAN $1917). RAB, however,
prevented more symptomatic recurrences (RAB 74% ver-
sus RAN 41%; ACER RAB $2748/recurrence prevented
versus RAN $4719/recurrence prevented). Excess physi-
cian visits and procedures with RAN offset RAB’s higher
cost. In sensitivity analysis, RAB remained more cost-
effective than RAN despite varying key clinical and cost
variables / 20%. The ICER of preventing one addi-
tional symptomatic recurrence with RAB rather than
RAN is $313.
CONCLUSION: RAB may be a cost-effective alternative
to RAN when modeling symptom relief in the manage-
ment of erosive esophagitis.
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TREATMENT OF DIABETIC FOOT ULCERS 
WITH TOPICAL RECOMBINANT GROWTH 
FACTOR GEL ACHIEVES HIGHER HEALING 
RATES AND RESULTS IN LOWER PROJECTED 
COSTS OF CARE
Martens L1, Zagari M1, Gagnon D1, Wieman TJ2
1ICOM Health Economics, Johnson & Johnson, Raritan, NJ, 
USA; 2Department of Surgical Oncology, University of 
Louisville, Louisville, KY, USA
OBJECTIVE: Diabetic foot ulcers are associated with
many adverse health outcomes and high treatment costs.
Wound infections, osteomyelitis, and amputations con-
tribute to wound-related costs of $4000 to $10,000 for an
episode of treatment, costs which may be partially avoided
with better wound management and improved healing
rates. Becaplermin gel, an FDA-approved topical recombi-
nant growth factor gel, has been shown to increase the in-
cidence of complete healing of full thickness, neuropathic,
diabetic foot ulcers (50% of patients treated with beca-
plermin gel plus good wound care versus 35% of patients
treated with placebo gel plus good wound care).
METHODS: A separate economic analysis was per-
formed for clinical trial data (20 weeks plus 12 weeks of
follow-up) using resource utilization determined from the
trial. Unit costs of resources were assigned from private
and US governmental cost databases. A state-transition
model was used to project resource use in the weeks fol-
lowing the clinical trial, up to 1 year.
RESULTS: After 20 weeks, average per-patient costs for
the control versus becaplermin gel groups were $4466
and $4817, respectively. Patients treated with becapler-
min gel had fewer hospitalizations, fewer outpatient vis-
its, and fewer debridements, but higher drug costs. By 29
weeks, treatment with becaplermin gel resulted in lower
projected overall treatment costs. Average per-patient
costs after 52 weeks were $10,416 (control) versus $9289
(becaplermin gel).
CONCLUSIONS: The analysis suggests that achieving a
better healing rate results in fewer overall resources used
and, consequently, lower projected costs of care.
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INCREASED UPPER GASTROINTESTINAL (UGI) 
DISTRESS AMONG ARTHRITIS PATIENTS 
TREATED WITH NSAIDS AS COMPARED TO 
CELECOXIB AND PLACEBO
Burke TA2, Goldstein JL1, Pettitt AD3, Maurath CJ2, Zhao SZ2, 
Zabinski RA2
1University of Illinois at Chicago, Chicago, IL, USA; 
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Upper gastrointestinal (UGI) symptoms are commonly
reported side effects in non-steroidal anti-inflamatory
(NSAID) users, often requiring physician intervention and
utilization of healthcare resources (e.g., endoscopy, acid-
suppression therapy). We hypothesize that a medication
associated with fewer UGI symptoms will result in signif-
icant clinical and healthcare utilization advantages over
existing NSAIDs.
OBJECTIVE: Quantify clinically significant UGI distress
among patients treated with celecoxib, a novel COX-2
inhibitor, compared to NSAIDs and placebo.
METHODS: Combined data from eight blinded celecoxib
phase III clinical trials of at least 12-weeks duration were
used (# subjects): celecoxib (3216), placebo (1136), and
NSAIDs (2427), divided among naproxen (1366), ibupro-
fen (345), and diclofenac (716). A composite UGI-symp-
